PTLA News and Press, Portola Pharmaceuticals Inc. From 02/11/20

New York, New York--(Newsfile Corp. - February 11, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola" or the "Company") of the March 16, 2020 deadline to seek the role of lead plaintiff in a fed...

New York, New York--(Newsfile Corp. - February 6, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) ("Portola" or the "Company") of the March 16, 2020 deadline to seek the role of lead plaintiff in a fede...

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. ("Portola" or the "Company")(NASDAQ:PTLA) of the March 16, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the...

NEW YORK , Feb. 3, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York , California and Georgia , announces an investigation of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) (" Portola ," or the "Company"). ...

SOUTH SAN FRANCISCO, Calif. , Feb. 3, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced the appointment of Rajiv Patni , M.D., as executive vice president and chief medical officer, effective immediately. Dr. Patni brings to his new role two decade...

Investment Thesis Portola bulls must be hugely frustrated by falling sales of the company's flagship drug - coagulation factor Xa (recombinant) Andexxa. Many people - myself included, when I recommended Portola in an article back in October - thought the company had a blockbuster on its...

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Portola Pharmaceuticals, Inc. ("Portola" or the "Company")(NASDAQ:PTLA) of the March 16, 2020 deadline to seek the role of lead plaintiff in a federal securitie...

Background Some historical matters may be in order. I am a retired clinical cardiologist with some consulting and executive experience in the pharmaceutical industry. Thus it was natural to be interested in Portola Pharmaceuticals ( PTLA ) when I came across it in 2014 (aka "The Year of Bi...

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Portola Pharmaceuticals, Inc. (“Portola” or the “Company”) (NASDAQ: PTLA ) investors concerning the Company and its officers’ possible violations of federal securi...

Gainers:  Sorrento Therapeutics (NASDAQ: SRNE )  +38% . More news on: Sorrento Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., Venus Concept Inc., Stocks on the move, Read more ...